CLL

Once I got the hang of administering subcutaneous immunoglobulin, my life was so much easier, as I no longer had to undergo monthly IV infusions for my cancer-related compromised immune system.

After being diagnosed with cancer 13 years ago, I began to wonder if my diet had anything to do with it — so I made some changes to eat better.

I made a point to continue baking a weekly challah bread after I was diagnosed with blood cancer, and it proved to be therapeutic.

After being diagnosed with lymphoma, I scheduled consultations with three oncologists, but only one provided me with the hope I needed.

Investigators of an expanded clinical trial have administered an investigational CAR-T cell therapy to the first patient with blood cancer.

Long-term clinical trial data showed that the use of Copiktra was associated with an increased rate of death and severe side effects for patients with chronic lymphocytic leukemia and small cell leukemia.

Treatment with Venclexta plus Gazyva, with or without Imbruvica, led to better outcomes than chemoimmunotherapy in patients with chronic lymphocytic leukemia.

Long-term study results show that outcomes, such as survival and response rates, in patients who have received Calquence-containing treatment regimens continue to outpace outcomes in those who were given Gazyva and chemotherapy.

A panel of experts on the FDA’s Oncologic Drugs Advisory Committee voted that all future approvals of PI3K inhibitors to treat blood cancer be backed by randomized clinical trial data.

The pharmaceutical company developing a combination regimen of ublituximab plus Ukoniq (known as U2) pulled the drug duo’s indications for the treatment of multiple types of blood cancer after clinical trial results fell short of improving overall survival.

The FDA’s partial hold means that no new patients with either leukemia or lymphoma can be enrolled onto the trial.

Regardless of whether it was guided by minimal residual disease status or given at a fixed dosage, consolidation Venclexta proved to be beneficial in patients with chronic lymphocytic leukemia.

Learn about the disproportionate impact that the COVID-19 pandemic has on immunocompromised patients with chronic lymphocytic leukemia (CLL), and hear potential solutions from leading CLL experts.

Regardless of a patient’s age, comorbidity status or disease risk, an expert from Memorial Sloan Kettering Cancer Center notes how targeted therapies have become the standard of care in treating chronic lymphocytic leukemia.

More research is necessary, says an expert, to improve responses to CAR-T cell treatments in patients with chronic lymphocytic leukemia.

Treatment with Calquence resulted in fewer toxicities, including atrial fibrillation, flutter and hypertension, in patients with previously treated chronic lymphocytic leukemia, compared with Imbruvica treatment, according to findings from the analysis of a phase 3 trial.

The combination of Calquence and Rituxan may also be useful during the COVID-19 pandemic as it decreases infusion times and patient interactions, according to an expert.

There are many cancer clinical trials that patients can enroll in across the United States. Here is a snapshot of some of the more recent ones.

Calquence, a next-generation BTK inhibitor, significantly prolonged survival compared with standard of care, along with no new side effects at three years in chronic lymphocytic leukemia. These findings also pertained to some patients with high-risk genetic features.

The data demonstrated that the combination of Imbruvica and Rituxan conferred superior progression-free survival results in patients with previously untreated chronic lymphocytic leukemia, compared with the chemotherapies fludarabine and cyclophosphamide plus Rituxan.

Patients with chronic lymphocytic leukemia reported improved quality of life when treated with frontline Imbruvica and Rituxan, followed by continuous treatment with Imbruvica.

Researchers found that depression and anxiety may skew patient perceptions of participating in blood cancer clinical trials, thus contributing to low enrollment throughout the United States.

Imbruvica plus Breyanzi, a CAR-T cell therapy, improved outcomes in patients with relapsed/refractory chronic lymphocytic leukemia, according to recent research.

The TRANSCEND CLL 004 trial is currently enrolling patients to determine the efficacy of a CAR-T cell therapy.

A fixed-duration treatment regimen may result in better outcomes and less time in the hospital for patients with CLL.